Titan Pharmaceuticals Announces Positive Results From Phase III Clinical Trial Of Probuphine For The Treatment Of ... (Medical News Today)
Titan Pharmaceuticals, Inc. (AMEX:TTP) announced positive, statistically significant results from its randomized, double-blind, placebo controlled, multi-center Phase III clinical trial of Probuphine . Probuphine is Titan's novel, subcutaneous implant formulation designed using its ProNeura technology to deliver six months of buprenorphine.

UC Irvine Extension Offers Clinical Data Management (Centre Daily Times)
The University of California, Irvine Extension, announces a new course for clinical data management professionals, clinical research associates, project managers, and programmers who support the design and development of clinical databases. The new course, "Clinical Data Management," will be offered online from Oct. 6 to Nov. 16.

Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches (Business Wire via Yahoo! Finance)
MIAMI----Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Stavzor in 125 mg, 250 mg and 500 mg strengths. Stavzor is approved for the treatment of manic episodes associated with bipolar disorder, as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association ...